Breast Oncology Program

乳腺肿瘤学项目

基本信息

批准号：
10712665
负责人：
Laura J Van't Veer
金额：
$ 18.33万
依托单位：
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
依托单位国家：
美国
项目类别：
财政年份：
1999
资助国家：
美国
起止时间：
1999-08-05 至 2028-05-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10712665
关键词：
Adverse effects Area Award Biology Breast Breast Cancer Risk Factor Breast Cancer Surveillance Consortium Breast Oncology Cancer Burden Cancer Center Support Grant Catchment Area Cells Classification Clinical Engineering Clinical Research Clinical Trials Communities Development Diagnosis Disease Drug Combinations Elements Ensure Ethnic Origin Extracellular Matrix Genetic Goals Healthcare Heterogeneity Individual Inflammation Intervention Laboratories Mammary Gland Parenchyma Mammographic screening Measures Methodology Methods Modeling Molecular Nature Neoadjuvant Therapy Neoplasm Metastasis Noninfiltrating Intraductal Carcinoma Oncogenic Outcome Participant Patient Outcomes Assessments Patient-Focused Outcomes Patients Pharmaceutical Preparations Phase Population Predisposition Prevention Prevention Measures Process Race Regimen Research Risk Risk Assessment Risk Reduction Safety Site Testing Therapeutic Time Tissues Training and Education Treatment outcome Tumor Tissue Woman Work breast lesion cancer risk cancer therapy cohort combinatorial community engagement demographics disorder risk drug development high risk improved improved outcome individualized medicine innovation insight malignant breast neoplasm member mortality neoplastic cell novel novel therapeutic intervention oncology program outcome disparities patient oriented personalized intervention personalized screening predicting response programs recruit response routine screening screening study population success therapy resistant trial design tumor tumor heterogeneity

项目摘要

Breast Oncology Program: Summary/Abstract The goal of the HDFCCC Breast Oncology (BR) Program is to reduce the risk of breast cancer development, progression, and mortality using innovative approaches and novel methodologies to reveal the molecular, cellular, and targetable networks that underlie susceptibility, heterogeneity, and outcome disparities. The translational nature of the program means that laboratory-based work in the program can be rapidly moved into clinical trials. The clinical research of the BR Program includes reducing overdiagnosis, over- and under- treatment, and the burden of cancer therapy through risk assessment to individualize screening and prevention measures, and through improved tumor classification to tailor treatment. BR research focuses on three areas: (1) understanding how tumor heterogeneity contributes to metastasis, dormancy, and therapeutic resistance; (2) developing new therapeutic strategies using innovation in trial design and drug development; and (3) better characterizing early breast lesions to improve screening, prevention, and health care value.

乳腺肿瘤学项目：总结/摘要 HDFCCC 乳腺肿瘤学 (BR) 计划的目标是降低患乳腺癌的风险，使用创新方法和新方法来揭示分子、细胞和可靶向网络是易感性、异质性和结果差异的基础。这该计划的转化性质意味着该计划中基于实验室的工作可以迅速转移到临床试验。 BR 计划的临床研究包括减少过度诊断、过度诊断和诊断不足通过风险评估进行个体化筛查和预防，了解癌症治疗的负担措施，并通过改进肿瘤分类来制定治疗方案。 BR研究主要集中在三个领域： (1) 了解肿瘤异质性如何影响转移、休眠和治疗耐药； (2) 利用试验设计和药物开发的创新来制定新的治疗策略； (3) 更好描述早期乳腺病变的特征，以提高筛查、预防和保健价值。